Este sitio requiere JavaScript habilitado para funcionar correctamente. Modifique su configuración o utilice otro navegador para continuar.

      

Esta usted abandonando la página de GSK.

El enlace le llevará a una página mantenida por un tercero, que es el único responsable de su contenido. GSK no controla, no influencia ni aprueba el sitio. Opiniones, quejas o comentarios expresados en este sitio no deben atribuirse a GSK.

Aceptar

Cancelar

WHY USE BENLYSTA®?

Some Key Facts About SLE and BENLYSTA Once-weekly Subcutaneous Injection

Before commencing initiation of BENLYSTA, it is important to note the special safety considerations with regard to infections, pregnancy and hypersensitivity reactions. Click here to access information on the special safety considerations

Find out more about the adverse event rates, safety and tolerability of BENLYSTA.

Click here to learn more about safety of BENLYSTA once-weekly subcutaneous injection

The Q&A section below will provide more details on why you should consider using BENLYSTA for your SLE patients.

*In patients with high disease activity (e.g., positive anti-dsDNA and low complement levels) despite standard therapy.
Standard therapies permitted, alone or in combination: corticosteroids (prednisone or prednisone equivalent, up to 40 mg/day), immunosuppressants, antimalarials, and NSAIDs
BLyS - B-lymphocyte stimulator.
#BENLYSTA was not studied in in combination with other B-cell targeted therapies (e.g. rituximab) or intravenous cyclophosphamide. As such, these combinations of therapies are not recommended. 7

References:

  1. Steiman AJ, Urowitz MB, Ibañez D, et al. Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol. 2014;41(9):1808-1816.
  2. Kalunian K, Joan TM. New directions in the treatment of systemic lupus erythematosus. Curr Med Res Opin. 2009;25:1501-1514.
  3. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967.
  4. Doria A, Gatto M, Zen M, et al. Optimizing outcome in SLE: treating to-target and definition of treatment goals. Autoimmun Rev. 2014;13(7):770-777.
  5. Katz P, Morris A, Trupin L, et al. Disability in valued life activities among individuals with systemic lupus erythematosus. Arthritis Rheum. 2008;59(4):465-473.
  6. Doria A, Stohl W, Schwarting A, et al. Efficacy and safety of subcutaneous belimumab plus standard care in patients with SLE with low complement and positive anti-dsDNA. Ann Rheum Dis. 2016;75(Supp.2):70.
  7. GlaxoSmithKline. Data on file.
  8. Cancro MP, D’Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 2009;119:1066-1073.
  9. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11):3253-3265.
  10. Liu Zh, Davidson A. Timing lupus – a new understanding of pathogenesis is leading to clinical advances. Nature Medicine. 2012;8(6):871-882.
  11. Vilas-Boas A, Morais SA, Isenberg DA. Belimumab in systemic lupus erythematosus. RMD Open. 2015;1: e000011. doi:10.1136/rmdopen-2014-000011.
  12. Sheikh SZ, Fox NL, Hammer AE, et al. Reliability and safety of a novel autoinjector for self-administration of subcutaneous belimumab in patients with systemic lupus erythematosus. Ann Rheum Dis. 2016;75(Suppl2):1048.